Our Pricing

How Cold Sore Tablets Work: Complete Guide

Understanding how do cold sore tablets work helps you make informed treatment decisions when that familiar tingling sensation starts. Cold sore tablets contain antiviral medications like aciclovir that block viral DNA replication at the cellular level, stopping the herpes simplex virus (HSV-1) from multiplying and reducing outbreak severity when taken early [1].

The Mechanism: How Aciclovir Stops Viral Replication

Aciclovir, the active ingredient in most cold sore tablets available in the UK, works through a highly selective mechanism that targets infected cells whilst leaving healthy cells unaffected [1]. Once absorbed, aciclovir enters cells throughout your body, but it only becomes active inside cells infected with the herpes simplex virus.

Inside infected cells, viral enzymes called thymidine kinase convert aciclovir into its active form—aciclovir triphosphate [1]. This activated molecule mimics the building blocks of viral DNA. When HSV-1 attempts to replicate its genetic material, it mistakenly incorporates aciclovir triphosphate instead of the natural nucleotide it needs [2].

This incorporation terminates the viral DNA chain, preventing the virus from completing replication [2]. Because human cells lack the specific viral thymidine kinase enzyme needed to activate aciclovir, the medication remains largely inactive in uninfected cells, minimising side effects whilst maximising antiviral activity where it's needed most.

Cold Sore Tablets vs Cream: Which Works Better?

The choice between oral tablets and topical cream depends on outbreak severity, frequency, and how early you catch the symptoms. Both contain aciclovir as the active ingredient, but they deliver it through different routes with distinct advantages.

Topical aciclovir cream, such as the Numark Cold Sore Cream available from £4.49, works locally at the application site. It's convenient for mild, infrequent outbreaks and doesn't require a prescription in the UK [3]. However, cream penetration is limited to surface tissues, and application must begin at the first sign of tingling for optimal results.

Oral aciclovir tablets provide systemic treatment, reaching higher concentrations in infected tissues throughout the body [3]. Clinical trials demonstrate that oral aciclovir reduces healing time by an average of 1-2 days when started within 48 hours of symptom onset, and can significantly reduce viral shedding [4]. For patients with frequent recurrences (six or more outbreaks yearly), suppressive therapy with daily oral aciclovir may reduce outbreak frequency by up to 80% [4].

When Tablets Offer Superior Outcomes

Oral tablets are particularly beneficial for severe primary infections, immunocompromised patients, or those experiencing frequent recurrences. The systemic delivery ensures consistent drug levels in all affected tissues, including areas difficult to reach with topical application. Patients who experience prodromal symptoms—tingling, itching, or burning before visible lesions appear—often achieve better results with tablets, as the medication circulates systemically before blisters form.

Timing Matters: Why Early Treatment Is Critical

The window for maximum antiviral efficacy is narrow. HSV-1 replicates exponentially in the first 24-48 hours after reactivation, with viral load peaking before visible blisters appear [5]. Starting aciclovir tablets during the prodromal phase—when you first notice tingling or itching—can prevent blister formation entirely in some cases.

Research shows that treatment initiated within 24 hours of symptom onset reduces lesion duration by approximately 2 days compared to delayed treatment [5]. After blisters have fully formed and begun crusting, antiviral tablets offer diminishing returns, as the bulk of viral replication has already occurred.

For patients prone to recurrent outbreaks, keeping a supply of prescribed aciclovir tablets at home enables immediate treatment at the first warning sign. This patient-initiated therapy approach, recommended by NICE guidance for recurrent herpes simplex infections, maximises treatment benefit whilst reducing overall outbreak severity and duration [6].

Dosing Schedules and Treatment Duration

Standard treatment for cold sore outbreaks in the UK involves aciclovir 200mg tablets taken five times daily for five days, or aciclovir 400mg tablets taken three times daily for five days [6]. Both regimens provide equivalent clinical outcomes, though the three-times-daily schedule often improves adherence.

For suppressive therapy in patients with frequent recurrences, the typical dose is aciclovir 400mg twice daily, continued for 6-12 months before reassessing outbreak frequency [6]. Some patients may require indefinite suppression if outbreaks resume after discontinuation. Your UK prescriber will determine the most appropriate dosing schedule based on your outbreak history and individual circumstances.

It's essential to complete the full course even if symptoms improve earlier. Premature discontinuation may allow residual virus to continue replicating, potentially prolonging the outbreak or increasing the risk of transmission during the infectious period.

Adjustments for Special Populations

Patients with renal impairment require dose adjustments, as aciclovir is primarily eliminated through the kidneys [1]. Elderly patients and those taking other nephrotoxic medications also warrant closer monitoring. Pregnant and breastfeeding women can generally use aciclovir when clinically indicated, as extensive safety data supports its use during pregnancy, though prescriber assessment is essential [7].

How Do Cold Sore Tablets Prevent Future Outbreaks?

Whilst aciclovir tablets cannot eliminate the latent HSV-1 virus residing in nerve ganglia, suppressive therapy significantly reduces reactivation frequency. The virus remains dormant in sensory nerve cells, periodically reactivating in response to triggers like stress, UV exposure, illness, or immune suppression [5].

Continuous low-dose aciclovir maintains therapeutic blood levels that suppress viral replication immediately upon reactivation, often preventing progression to symptomatic lesions [4]. Clinical studies show that patients on suppressive therapy experience 70-80% fewer outbreaks compared to placebo, with many remaining outbreak-free for extended periods [4].

Beyond reducing personal discomfort, suppressive therapy also decreases asymptomatic viral shedding—periods when the virus is present on skin or mucous membranes without visible symptoms [8]. This reduction in shedding may lower transmission risk to close contacts, though safe practices remain essential as suppressive therapy doesn't eliminate transmission risk entirely.

Side Effects and Safety Considerations

Aciclovir tablets are generally well-tolerated, with most patients experiencing no significant adverse effects. The most commonly reported side effects include headache, nausea, and mild gastrointestinal upset, occurring in approximately 1-10% of users [1]. These effects are typically mild and resolve without intervention.

Rare but serious side effects include renal impairment, particularly in patients with pre-existing kidney disease or dehydration. Maintaining adequate hydration during treatment helps minimise this risk [1]. Neurological effects such as confusion, hallucinations, or tremors occur very rarely, predominantly in elderly patients or those with renal dysfunction [7].

Aciclovir has been used safely for over four decades with an excellent long-term safety profile. Drug interactions are minimal, though caution is advised when combining with other nephrotoxic medications or drugs that affect renal function. Your UK prescriber will review your complete medication history during the online consultation to ensure aciclovir is appropriate for you.

When to Seek Medical Advice

Contact a healthcare professional if cold sores persist beyond two weeks despite treatment, if you develop eye symptoms (which may indicate ocular herpes), if outbreaks become increasingly frequent or severe, or if you're immunocompromised. Patients experiencing their first cold sore outbreak should also seek medical assessment, as primary HSV-1 infections can be more severe than recurrences and may warrant extended treatment.

Scientific References

1. De Clercq, E., & Field, H. J. (2006). Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. British Journal of Pharmacology, 147(1), 1–11. https://doi.org/10.1038/sj.bjp.0706446
2. Elion, G. B., Furman, P. A., Fyfe, J. A., de Miranda, P., Beauchamp, L., & Schaeffer, H. J. (1977). Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proceedings of the National Academy of Sciences, 74(12), 5716–5720. https://doi.org/10.1073/pnas.74.12.5716
3. Spruance, S. L., Rea, T. L., Thoming, C., Tucker, R., Saltzman, R., & Boon, R. (1997). Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. JAMA, 277(17), 1374–1379.
4. Rooney, J. F., Straus, S. E., Mannix, M. L., Wohlenberg, C. R., Alling, D. W., Dumois, J. A., & Notkins, A. L. (1993). Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Annals of Internal Medicine, 118(4), 268–272. https://doi.org/10.7326/0003-4819-118-4-199302150-00004
5. Spruance, S. L., Overall, J. C., Kern, E. R., Krueger, G. G., Pliam, V., & Miller, W. (1977). The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. New England Journal of Medicine, 297(2), 69–75. https://doi.org/10.1056/NEJM197707142970201
6. National Institute for Health and Care Excellence. (2023). Herpes simplex – oral. NICE Clinical Knowledge Summaries. https://cks.nice.org.uk/topics/herpes-simplex-oral/
7. Pasternak, B., & Hviid, A. (2010). Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA, 304(8), 859–866. https://doi.org/10.1001/jama.2010.1206
8. Wald, A., Corey, L., Cone, R., Hobson, A., Davis, G., & Zeh, J. (1997). Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. Journal of Clinical Investigation, 99(5), 1092–1097. https://doi.org/10.1172/JCI119237

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.